A. Zeidan, A. Fathi, G. Issa, H. Erba, J. Ahsan, Daniel Corum, B. Tomkinson, T. Kozlek, M. Leoni, E. Wang
{"title":"AML-516 KOMET-007试验正在进行中:Ziftomenib联合Venetoclax或Venetoclax/阿扎胞苷,或标准诱导阿糖胞苷/柔红霉素(7+3)化疗联合Ziftomenib治疗急性髓系白血病患者的I期研究","authors":"A. Zeidan, A. Fathi, G. Issa, H. Erba, J. Ahsan, Daniel Corum, B. Tomkinson, T. Kozlek, M. Leoni, E. Wang","doi":"10.1016/s2152-2650(23)01074-1","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10370,"journal":{"name":"Clinical Lymphoma Myeloma and Leukemia","volume":"11 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AML-516 KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia\",\"authors\":\"A. Zeidan, A. Fathi, G. Issa, H. Erba, J. Ahsan, Daniel Corum, B. Tomkinson, T. Kozlek, M. Leoni, E. Wang\",\"doi\":\"10.1016/s2152-2650(23)01074-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10370,\"journal\":{\"name\":\"Clinical Lymphoma Myeloma and Leukemia\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma Myeloma and Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s2152-2650(23)01074-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma Myeloma and Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s2152-2650(23)01074-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
AML-516 KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia